X

Trial Profile

An Open Label Ascending Dose Study Evaluating the Safety/Tolerability, Pharmacokinetic and Pharmacodynamic Effects of KA2507 in Patients With Solid Tumours

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs KA 2507 (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Head and neck cancer; Nasopharyngeal cancer; Oesophageal cancer; Prostate cancer; Salivary gland cancer; Sarcoma; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man
Acronyms HDAC6i
Sponsors Karus Therapeutics

Most Recent Events

04 May 2021 Results published in the Clinical Cancer Research
06 Aug 2020 Status changed from recruiting to completed.
28 Apr 2020 Interim results (n=20) presented at the 111th Annual Meeting of the American Association for Cancer Research - I

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com